Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39035
Title: | Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO | Authors: | Oreja-Guevara, C. Benedict, R. H. Comi, G. Cutter, G. Kister, I. Siva, A. Wiendl, H. VAN WIJMEERSCH, Bart Wuerfel, J. El Azzouzi, B. Buffels, R. Dirks, P. Kuenzel, T. Vermersch, P. |
Issue Date: | 2022 | Publisher: | SAGE PUBLICATIONS LTD | Source: | Multiple Sclerosis Journal, 28 (S3) , p. 327 -329 | Document URI: | http://hdl.handle.net/1942/39035 | ISSN: | 1352-4585 | e-ISSN: | 1477-0970 | ISI #: | 000866540801286 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Efficacy and safety of ocrelizumab is maintained in patients with RRMS with.pdf | Published version | 7.08 MB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.